Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit reported in Q3 of the previous financial year.
The reported net profit is higher with the Rs 1,225 crore average net profit estimated by 10 brokerages polled by Moneycontrol.
The company reported its highest ever quarterly revenue from operations at Rs 7,073 crore. This marks an increase of 7 percent from the Rs 6,604 crore revenue reported in the same period of FY24. Notably, the reported revenue is also higher than the estimated Rs 6,925 crore, as per Moneycontrol's poll.
Cipla's EBITDA jumped nearly 16 percent year-on-year to Rs 1,989 crore. Its EBITDA margin during the quarter stood at 28.1 percent, up from the 26.3 percent reported in the same period of the previous financial year.
Cipla's total expenses saw a 5 percent rise to Rs 5,378 crore in Q3 FY25 from Rs 5,120 crore in Q3 FY24. Its basic earnings per equity share (EPS) stood at Rs 19.45 during the reported quarter.
The company reported that its India business has grown 10 percent year-on-year. "Branded Prescription business continued to outpace the market growth in key therapies, Trade Generics is back on growth trajectory and Anchor brands of CHL continued to grow bigger," it said.
The company reported a revenue of $227 million for its North America business, overcoming tumor drug Lanreotide supply shortfall. The management had informed about supply disruptions in Lanreotide last quarter, which was expected to normalise around Q4. Accordingly, US sales below $220 million for Q3 was guided.
Cipla MD and Global CEO Umang Vohra said: "I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S…Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."
Cipla shares positively reacted to the Q3 results. After hitting an intraday low of Rs 1,367, the shares sharply jumped to trade at Rs 1,470 (over 5 percent higher) at 2.16 pm on January 28.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
